Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines

被引:124
|
作者
Choudhury, A
Charo, J
Parapuram, SK
Hunt, RC
Hunt, DM
Seliger, B
Kiessling, R
机构
[1] Karolinska Inst, Dept Oncol Pathol, CCK, IGT, S-17176 Stockholm, Sweden
[2] Univ Mainz, Dept Internal Med, D-6500 Mainz, Germany
[3] Univ S Carolina, Sch Med, Dept Pathol & Microbiol, Columbia, MO USA
关键词
siRNA; Her-2/neu; RNAi; oncogene; breast cancer;
D O I
10.1002/ijc.11497
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Silencing of a specific mRNA using double stranded RNA oligonucleotides represents one of the newest technologies for suppressing a specific gene product. Small interfering RNA (siRNA) are 21 nucleotides long, double stranded RNA fragments that are identical in sequence to the target mRNA. We designed 3 such siRNA against the Her2/neu (HER2) gene. The HER2 gene is known to play an important role in the oncogenesis of several types of cancers, such as breast, ovarian, colon and gastric cancers. Introduction of the siRNA into HER2 positive tumor lines in vitro greatly reduced the cell surface expression of the HER2 protein. Concurrently, a range of effects on cell physiology, such as growth inhibition or apoptosis, was observed. The expression of HLA class I was observed to be upregulated when HER2 was silenced with siRNA. Treatment of SKBr3 and MCF7/HER2 tumor cell lines with the HER2 siRNA resulted in growth arrest of cells in the late G(1)/S-phase. Our results suggest that siRNA may be an effective method of abrogating the effect of HER2 in tumorigenesis. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:71 / 77
页数:7
相关论文
共 50 条
  • [41] Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway
    Way, TD
    Kao, MC
    Lin, JK
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (06) : 4479 - 4489
  • [42] Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/Neu
    Piechocki, Marie P.
    Yoo, George H.
    Dibbley, Susan K.
    Amjad, Esmael H.
    Lonardo, Fulvio
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (02) : 441 - 454
  • [43] Expression of Her2/neu receptor in carcinoma gallbladder correlates significantly with advanced tumor stage
    Ashai, Farzana
    Ashraf, Aadil
    Rashid, Arshad
    Banday, Bilal Musharaf
    Bhalla, Sunita
    Dhawan, Shashi
    INTERNATIONAL JOURNAL OF HEPATOBILIARY AND PANCREATIC DISEASES, 2015, 5 (02): : 86 - 91
  • [44] Correlation of HER-2/Neu Protein Expression and HER2 Gene Amplification with Clinical Morphological Parameters of Nonsmall Cell Lung Cancer
    D. S. Kobyakov
    A. M. Avdalyan
    I. P. Bobrov
    E. Yu. Bychkova
    A. F. Lazarev
    E. L. Lushnikova
    L. M. Nepomnyashchikh
    Bulletin of Experimental Biology and Medicine, 2014, 157 : 789 - 793
  • [45] Correlation of HER-2/Neu Protein Expression and HER2 Gene Amplification with Clinical Morphological Parameters of Nonsmall Cell Lung Cancer
    Kobyakov, D. S.
    Avdalyan, A. M.
    Bobrov, I. P.
    Bychkova, E. Yu.
    Lazarev, A. F.
    Lushnikova, E. L.
    Nepomnyashchikh, L. M.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2014, 157 (06) : 789 - 793
  • [46] Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancer
    Zhang, Xiuli
    Qu, Jianhui
    Sun, Gang
    Yang, Jing
    Yang, Yunsheng
    ONCOLOGY LETTERS, 2010, 1 (03) : 559 - 563
  • [47] A trimeric anti-HER2/neu ScFv and tumor necrosis factor-α fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia
    Huang, TH
    Morrison, SL
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (03): : 983 - 991
  • [48] Enhancing HER2/neu Specific T-cell Therapy by Targeting the Tumor Endothelium
    Vy Phan Lai
    Buckanovich, Ronald J.
    Gad, Ekram
    Bigdeli, Laleh
    Disis, Mary L.
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [49] Enhanced HER2/neu specific T-cell immunity in vitro by HER2/neu Ii-key modified "agonist" class II peptides in breast cancer patients.
    Murray, JL
    Kawano, K
    Efferson, C
    Babiera, G
    Meric-Bernstam, F
    Ibrahim, N
    Kallinteris, NL
    Humphreys, RE
    Von Hofe, E
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S198 - S198
  • [50] Induction of NK cell ADCC against Her2/neu expressing ALL blasts by Trastuzumab in vitro and long term clinical follow-up of Her2/neu positive ALL patients
    Haen, S. P.
    Schmiedel, B. J.
    Roth, N.
    Moehle, R.
    Faul, C.
    Schmalzing, M.
    Kanz, L.
    Vogel, W.
    Salih, H. R.
    ONKOLOGIE, 2012, 35 : 113 - 114